March 2020

Home  /  2020  /  March

This is the pharmaceutical Joint Assessment PTJA09 on brolucizumab. In February 2020, the European Commission granted marketing authorisation for Beovu® (brolucizumab) for the treatment of adults with neovascular (wet) AMD. This Joint Assessment aims to compare the clinical effectiveness and

The aim of this guidance document is to pass on some knowledge and know-how to all stakeholders with an interest in economic evaluations by providing an overview of important points for consideration when performing/assessing such evaluations, supported by a selection